85 FR 56 pgs. 16368-16369 - Blood Products Advisory Committee; Postponed

Next Article Next

Type: NOTICEVolume: 85Number: 56Pages: 16368 - 16369

Docket number: [Docket No. FDA-2020-N-0008]

FR document: [FR Doc. 2020-06082 Filed 3-20-20; 8:45 am]

Agency: Health and Human Services Department

Sub Agency: Food and Drug Administration

Official PDF Version: PDF Version

Pages: 16368, 16369

[top]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0008]

Blood Products Advisory Committee; Postponed

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

[top] The meeting of the Blood Products Advisory Committee (BPAC) scheduled for April 2-3, 2020, is postponed. The Food and Drug Administration (FDA), like other government agencies, is taking the necessary steps to ensure the Agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the

COVID-19 public health emergency. Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Therefore, this meeting is being postponed. The meeting was announced in the Federal Register on February 13, 2020.

FOR FURTHER INFORMATION CONTACT:

Christina Vert, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6268, Silver Spring, MD 20993-0002, 240-402-8054, christina.vert@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the Federal Register of February 13, 2020, 85 FR 8299.

Dated: March 18, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2020-06082 Filed 3-20-20; 8:45 am]

BILLING CODE 4164-01-P